
HPV infections pose serious risks for both men and women, experts say
Gilles Charette first noticed something was going on with his body when he found an anal wart during a shower.
Charette confirmed with a nurse practitioner that he had acquired a human papillomavirus (HPV) infection, and quickly received topical ointment for treatment.
As a gay man in an open marriage, Charette also decided to get the HPV vaccine, choosing to pay out of pocket to be immunized rather than risk another HPV infection or HPV-associated cancer.
"The recommendation was to [get vaccinated]," said Charette, who is the director of the Gay Men's Sexual Health Alliance in Toronto.
"And so I did."
HPV is one of the most common sexually transmitted infections in Canada and the world, and is estimated to be responsible for five per cent of all cancer cases globally.
HPV infection is most commonly associated with cervical cancer, since roughly 99 per cent of all cervical cancer cases are connected to HPV. But experts warn that HPV is a virus that affects all sexually active people and can lead to a variety of cancers — regardless of gender.
"We tend to focus on women because of the concern with cervix cancer … but in fact men also carry and can be infected and affected by HPV," University of British Columbia (UBC) professor Dr. Deborah Money, told Dr. Brian Goldman, host of CBC's The Dose.
How common is HPV?
The Public Health Agency of Canada (PHAC) estimates that roughly three quarters of sexually active men and women will have at least one HPV infection in their lifetime.
"The good news is that, in fact for most people, it's a transient infection and it's cleared and it just goes away," said Money, who heads the UBC faculty of medicine's department of obstetrics and gynaecology (OBGYN).
While HPV infection is dangerous for women because of the risk of cervical cancer, HPV is dangerous for gay, bisexual and other men who have sex with men because of concerns over genital and anal cancer.
Of the more than 100 strains of HPV that exist in nature, two strains cause the majority of cancer cases associated with HPV, including cancers of the cervix, vagina, vulva, penis and anus.
However, HPV infections can also lead to cancers of the throat, tongue and tonsils.
WATCH | Calls for schools, pharmacies to boost lagging HPV vaccination rates for kids:
Calls for schools, pharmacies to boost lagging HPV vaccination rates for kids
3 years ago
Duration 2:02
Gilla Shapiro, a psychologist at the Princess Margaret Cancer Centre and faculty member of the Centre for Vaccine Preventable Diseases at the Dalla Lana School of Public Health, says rates of mouth and throat cancers are on the rise for men and women in Canada, but at a faster rate for men.
According to numbers from the Canadian Cancer Statistics Dashboard, male head and neck cancer rates were 2.7 times higher than female head and neck cancer rates in 2019, with 2024 rates projected to be 2.8 times higher for men versus women.
In communities of men who have sex with men, HIV/AIDS status is more openly discussed than whether someone has had HPV, according to Charette. bBut he notes that an HPV infection can be especially detrimental for people who are HIV positive.
A 2020 review looking at the relationship between HIV status and HPV-related cancers in sub-Saharan Africa found that HIV positivity is associated with an increased prevalence of HPV infection, "which will result in increased burden of HPV-related cancers among [people living with HIV]," according to the authors.
"So certainly people living with HIV should be considering HPV vaccination," said Charette.
PHAC recommends that immunocompromised individuals — including people living with HIV — receive three-dose schedule of the Gardasil-9 vaccine.
It estimates that 25 to 35 per cent of mouth and throat cancers are associated with oral HPV infection.
The Canadian Cancer Society estimates that 90 per cent of people with anal cancer also have an HPV infection.
HPV vaccines lead to reduced cancer rates, research shows
Experts agree the easiest way to prevent HPV infection is through one of the two approved HPV vaccines: Gardasil-9 and Cervarix.
Gardasil-9, which protects against nine types of HPV, is available for men and women, between the ages of nine and 45.
Cervarix, approved for women aged nine to 45, protects against the two high-risk HPV types that cause approximately 70 per cent of all cervical cancer cases.
A 2022 U.S. review found that an earlier version of Gardasil, which protected against four strains of HPV, was 90 per cent effective at reducing genital warts in males, and 77.5 per cent effective in reducing anal intraepithelial neoplasia in males, a precancerous condition that causes abnormal changes to the lining of the anal canal.
According to research published by the Canadian Partnership Against Cancer, HPV immunization before the age of 17 leads to a 90 per cent reduction in invasive cervical cancer risk, while HPV immunization before the age of 30 leads to a 50 per cent reduction in cervical cancer risk.
WATCH | Canada's cancer screening guidelines are out of date, doctors say:
Canada's cancer screening guidelines are out of date, doctors say
10 months ago
Duration 0:01
A group of cancer experts say Canadian national screening guidelines are a decade out of date, which is leading to people getting diagnosed later, when they are more difficult to treat.
"They're much more effective than many of the vaccines we use," said Money.
HPV vaccines are usually offered to school-aged boys and girls, ideally before the average age that they begin engaging in sexual activity.
Nonetheless, even people who are already sexually active can benefit from the HPV vaccine, because the likelihood that someone has been exposed to every type of HPV that the vaccine protects against is low, according to B.C. Cancer.
A Health Canada spokesperson confirmed that the National Advisory Committee on Immunization (NACI) recommends HPV vaccines for people between nine and 26 years of age.
"[NACI] also recommends vaccination of individuals 27 years of age and older following a consultation with a health-care provider, in consideration of risk factors which may lead to infection with the human papilloma viruses," wrote Health Canada via email.
NACI estimates that vaccine uptake for at least one dose is higher among females than males. Roughly 77 per cent of females have at least one HPV vaccine dose according to 2023 numbers, compared to 75 per cent of males.
The vaccine is free for males and females under the age of 26, typically through school-based and catch-up programs in every province and territory, according to the Canadian Partnership Against Cancer.
If you're older than 26 in most parts of Canada, however, you will have to pay out of pocket, like Charette.
He says the price of the HPV vaccine for those not eligible for free programs — $215 per dose in Toronto, for example — can be prohibitive for some.
Shapiro says there are programs developed to support the vaccination of gay, bisexual and other men who have sex with men, "because of the higher risk of developing certain types of HPV associated cancers."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
2 days ago
- Cision Canada
The BC Centre for Excellence in HIV/AIDS national Summit raises alarm about rising incidence of HIV in Canada and threats to global progress
Delegates call on Prime Minister to end the Canadian epidemic and lead the worldwide HIV response in light of dramatic US cuts to treatment and care VANCOUVER, BC, June 6, 2025 /CNW/ - The BC Centre for Excellence in HIV/AIDS (BC-CfE) is hosting a national Summit of medical and HIV experts to raise the alarm about the rising incidence of HIV in Canada, the immense threat that US cuts to HIV programs pose to millions at risk of disease and death globally, and the need for Canadian leadership to help prevent a resurgence in HIV/AIDS. Despite the groundbreaking work done to implement the BC-CfE's Treatment as Prevention ® (TasP ®) and HIV Pre-Exposure Prophylaxis (PrEP) programs in many jurisdictions, Canada is losing ground to HIV/AIDS across the country. The latest available government statistics for 2023 show a 35% uptick in HIV cases in Canada compared to 2022. Anecdotal discussions between BC-CfE and HIV experts across Canada indicate the situation continues to deteriorate, with HIV incidence statistics expected to be higher yet again in 2024 and in 2025. Meanwhile, the United States has substantially decreased funding to domestic programs currently supported by the US Centers for Disease Control and Prevention and Medicare, and international programs supported by PEPFAR (the US President's Emergency Plan for AIDS Relief) and USAID. UNAIDS estimates another 6.6 million new HIV infections and 4.2 million AIDS-related deaths between 2025 and 2029 if US government cuts continue. At the National TasP Summit, Dr. Julio Montaner, BC-CfE Executive Director & Physician-in-Chief, called on Prime Minister Mark Carney to take the reins and redouble efforts to end the Canadian HIV/AIDS epidemic by 2030, fully fund Highly Active Antiretroviral Therapy (HAART) and PrEP within a national pharmacare plan, and meet the UNAIDS 95-95-95 target for HIV testing, treatment and viral suppression. Meeting the UNAIDS targets * would result in a 90% reduction in HIV/AIDS-related deaths and new infections by 2030, ending the HIV/AIDS epidemic as a public health threat. "The Prime Minister has called for cost-effective, nation-building projects to improve the lives of Canadians and show leadership," said Dr. Montaner. "Redoubling efforts to defeat HIV/AIDS in Canada by 2030 fits the bill. It saves lives, prevents disease progression, improves quality of life and saves money. We have a plan. We need the Prime Minister's help to get it over the finish line." In addition, Canada must step up to better support the Global Fund to Fight AIDS, Tuberculosis and Malaria, to provide much-needed international leadership in a renewed and reinvigorated fight against HIV/AIDS. Weakening global efforts for HIV prevention, treatment, and support are already having an impact in British Columbia and throughout Canada. Domestically, HIV prevention and treatment strategies have saved countless lives and dramatically improved the lives of people living with and at-risk of HIV. However, many of Canada's new HIV cases relate to domestic and international migration, demonstrating the need for federal unity in Canada's HIV response and better support for the Global Fund. "HIV does not respect provincial, Canadian or international borders," said Summit co-chair Dr. Val Montessori, BC-CfE Director of Clinical Education. "With new HIV diagnoses rising across Canada, the need is greater than ever to implement proven HIV prevention and treatment strategies. By working together, we can strengthen the national HIV response in Canada and around the world, improve the lives of people living with HIV, and prevent new cases." *About the UNAIDS 95-95-95 Targets Based on the Treatment as Prevention strategy developed by the BC-CfE, the United Nations Joint Programme on HIV/AIDS (UNAIDS) set out ambitious targets in 2014 to end the AIDS epidemic globally by 2030. This culminated in the UN 95-95-95 Targets, which established that countries ensure 95% of people living with HIV are diagnosed, 95% of those diagnosed are on treatment, and 95% of those on treatment are virally suppressed, by the year 2025. Meeting the UN Targets would change the trajectory of the epidemic so that we would see a 90% reduction in HIV/AIDS related deaths and new HIV infections by 2030, which would herald the end of the HIV/AIDS epidemic as a public health threat. About the British Columbia Centre for Excellence in HIV/AIDS The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility – nationally and internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. The made-in-BC Treatment as Prevention ® strategy (TasP ®) pioneered by BC-CfE, and adopted by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the United Nations' 90-90-90 Target by 2020 and current UN 95-95-95 Target by 2025 – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP ® to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination ® as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, health care providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world.


CBC
3 days ago
- CBC
A book prescription for mental health?
On the surface, it may seem that bibliotherapy is another personal wellness trend. The practice promotes books and literature as touchstones, to aid mental health and healing. While it's true that anyone can offer book recommendations, there is evidence in the scientific literature to support its clinical use by mental health practitioners. "It's recommended in the Canadian guidelines for treatment of depression and anxiety," said Victoria-based psychiatrist Martina Scholtens. Bibliotherapy is one of the mental health approaches that she makes use of in her private practice, for certain patients. She might prescribe poetry or a memoir, a novel or workbook. "I want the prescription to be evidence-based and tailored to the recipient of the book and their very particular circumstances," she said. Dr. Scholtens, who is a clinical assistant professor of medicine at the University of British Columbia, put together a list of recommended titles, based on evidence. "I wanted to make book prescriptions more accessible to patients and their caregivers by reviewing, organizing, and disseminating recommended reading lists." She first published the extensively-researched list as an academic paper in 2024, but has now created a website for it, divided by diagnosis, at Bibliotherapy as an art Bibliotherapy can range from a science-based approach, to one that is primarily literary. Brooklyn journalist Cody Delistraty sought out an arts-based bibliotherapist when researching ways to address the prolonged grief he felt after the death of his mother. Then in his early 20s, Delistraty undertook a number of experiments and therapies. "I love to read, I love to write. So [bibliotherapy] made sense for me to dive into," said the author of The Grief Cure: Looking for the End of Loss. After an "odd, not-your-usual therapy session" and an intensive reading questionnaire, English bibliotherapist Ella Berthoud furnished him with an annotated and personalized list of international fiction. He particularly resonated with Sum, a collection of surreal and witty short stories by neuroscientist David Eagleman. "Grief can feel so sacred and so scary," said Delistraty. "To realize that it's just part of the wildness and the absurdity of life had the peculiar effect of helping me to really see the world through a new lens." Literary caregiving A Hundred Years of Bibliotherapy: Healing Through Books, is a new essay collection edited by three researchers from the UK's Open University. It takes a historical survey of the practice. "The term bibliotherapy was coined by an American Unitarian minister called Samuel McChord Crothers in 1916," said 20th-century literature professor Sara Haslam. "The First World War is certainly a key inflection point." America's institutionally-backed Library War Service set up military camp libraries at the start of the First World War. At U.S. military hospitals, books were prescribed and dispensed to wounded soldiers by uniformed librarians. The British version of bibliotherapy was somewhat less prescriptive and medicalized. Sara Haslam calls it "literary caregiving." In places like the female-run Endell Street Military Hospital, "it wasn't about medicalizing books as part of soldiers' recovery. It was about freeing wounded and sick soldiers to identify the kind of reading that they wanted to do." Haslam discovered archival proof that a substantial UK war library was amassed by 1917, spearheaded by one woman. Donations poured in from the public after May Gaskell's emotional call-out asking for meaningful books for soldiers. "I see these books as invested with caregiving from the donating public. They gave things that were precious, that they loved. So it went a long way to meeting the need that was being expressed by those who were fighting." Reading in a digital era A hundred years later, it seems that bibliotherapy has been experiencing a renaissance. Two more new books about bibliotherapy are being published this spring: one by bibliotherapist Bijal Shah, and another from social worker Emely Rumble. Edmund King, a co-editor of A Hundred Years of Bibliotherapy, is a historian of reading. He has a theory for the resurgence. "I think the reason that we're so obsessed now with the idea that books can heal, or are good for us, is because we also fear the end of reading." Despite the rise of BookTok, the books community populated by users of TikTok, King worries about the decline of time young people spend with books. "The literary culture that we value so much might be coming to an end." Yet throughout the history of reading, he says, it has been imbued with "this great power to change people's minds, change the way we see the world, transfer thoughts from one mind to another, preserve ideas, transmit ideas to different times and different contexts." For Sara Haslam, books remain powerful. In her view, opening a book is always surprising, and inherently conducive to mental health. "It's a moment when you are in the present. You have slowed down," she said. "I think it's fair to say that there is a wide readership of all ages who still recognize that that moment in engagement with a book is irreplaceable. "And long may that continue." *Written and produced by Lisa Godfrey. Guests in this episode: Martina Scholtens is a psychiatrist in Victoria, and a clinical assistant professor at UBC Faculty of Medicine. She is the author of Your Heart Is the Size of Your Fist: A Doctor Reflects on Ten Years at a Refugee Clinic.


Cision Canada
4 days ago
- Cision Canada
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert ® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030. 1 "Xpert ® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert ® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert ® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578 About Cepheid Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit